Alpelisib + Alpelisib matching Placebo + Trastuzumab + Pertuzumab
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced HER2+Breast Cancer
Conditions
Advanced HER2+Breast Cancer
Trial Timeline
Jul 16, 2020 → Feb 26, 2027
NCT ID
NCT04208178About Alpelisib + Alpelisib matching Placebo + Trastuzumab + Pertuzumab
Alpelisib + Alpelisib matching Placebo + Trastuzumab + Pertuzumab is a phase 3 stage product being developed by Novartis for Advanced HER2+Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04208178. Target conditions include Advanced HER2+Breast Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced HER2+Breast Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04208178 | Phase 3 | Active |
Competing Products
20 competing products in Advanced HER2+Breast Cancer